Topical Timolol for Periocular Hemangioma: Report of Further Study

Ni, Nina

doi:10.1001/archophthalmol.2011.24

Cited by 80 publications

(80 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…190 Case reports and case series have shown a good response of IH to twice-daily topical application of timolol. [191][192][193][194][195] In a randomized controlled trial, timolol was more effective than placebo in reducing the size and color intensity of small superficial IHs. 196 Laboratory studies were not monitored in the majority of studies, and only 1 infant in 1 large series developed a transient sleep disturbance.…”

Section: Topical B-adrenergic Blockersmentioning

confidence: 99%

“…194,311 This drug has replaced other topical therapies such as imiquimod, which causes significant irritation of the skin, conjunctiva, and cornea, and topical steroids, which carry the risk of glaucoma and cataract formation. Laser treatment (PDL) can also be very effective in treating superficial periocular IHs but usually requires corneal protection and general anesthesia.…”

Section: Highlights Of This Sectionmentioning

confidence: 99%

See 1 more Smart Citation

Diagnosis and Management of Infantile Hemangioma

Darrow¹,

Mancini²,

Nopper³

et al. 2015

Pediatrics

211

290

View full text Add to dashboard Cite

Infantile hemangiomas (IHs) are the most common tumors of childhood. Unlike other tumors, they have the unique ability to involute after proliferation, often leading primary care providers to assume they will resolve without intervention or consequence. Unfortunately, a subset of IHs rapidly develop complications, resulting in pain, functional impairment, or permanent disfigurement. As a result, the primary clinician has the task of determining which lesions require early consultation with a specialist. Although several recent reviews have been published, this clinical report is the first based on input from individuals representing the many specialties involved in the treatment of IH. Its purpose is to update the pediatric community regarding recent discoveries in IH pathogenesis, treatment, and clinical associations and to provide a basis for clinical decision-making in the management of IH.

show abstract

Section: Topical B-adrenergic Blockersmentioning

confidence: 99%

Section: Highlights Of This Sectionmentioning

confidence: 99%

Diagnosis and Management of Infantile Hemangioma

Darrow¹,

Mancini²,

Nopper³

et al. 2015

Pediatrics

211

290

View full text Add to dashboard Cite

show abstract

“…The drug is available as a 0.1% or 0.5% solution or gel formulation. Several case reports/series give evidence about its efficacy for small, superficial IHs (3)(4)(5)(6).…”

Section: Timolol Maleatementioning

confidence: 99%

“…The only side effect observed after patch application is skin irritation with 20% timolol. When used to treat IHs, 0.1% and 0.5% timolol maleate has so far not given any systemic adverse reactions (3)(4)(5). Nevertheless, the available safety data are still insufficient, and specialists involved in the treatment with timolol should be alert about the side effects of beta-blocker and monitor infants accordingly.…”

Section: Timolol Maleatementioning

confidence: 99%

Topical Treatment of Infantile Hemangiomas – Where Are We Now? / Topikalni tretman infantilnih hemangioma – gde smo danas?

Semkova¹,

Marina²,

Kazandjieva³

2011

Serbian Journal of Dermatology and Venerology

View full text Add to dashboard Cite

Infantile hemangiomas are the most common, benign vascular tumors of infancy. Their main feature is spontaneous involution over months to years after an initial phase of rapid proliferation. Small, superficial lesions usually resolve without sequel, but scarring and disfigurement are still possible, while the cosmetic outcome is unpredictable. Thus, inflantile hemangiomas benefit from non-aggressive topical treatment, because it is safe and with an overall outcome comparable to spontaneous involution. The available topical agents reported in the literature to satisfy these requirements are topical beta-blockers, imiquimod and topical corticosteroids. However, none of these have been assessed in randomized controlled trials, and standardized treatment recommendations about precise dosing and patient selection are not available yet.

show abstract

“…Timolol, a topical beta-blocker with less risk of systemic effect, was first used to treat periorbital hemangiomas [7,8], and subsequently found useful for hemangiomas elsewhere, but not all patients respond well to it. The 595 nm pulse dye laser (PDL) is another effective treatment for hemangiomas [9][10][11][12].…”

Section: Introductionmentioning

confidence: 99%

Novel Combination Topical Timolol and Pulsed Dye Laser Therapy for Early Effective Safe Treatment of Infantile Hemangiomas

Chang¹,

Kang²

2017

J Clin Exp Dermatol Res

View full text Add to dashboard Cite

Introduction: Infantile Hemangiomas (IH) are the most common benign pediatric tumors and carry potential cosmetic and functional sequelae. Topical timolol and Pulsed Dye Laser (PDL) are effective IH therapies and previous studies have suggested the superiority of combination timolol-PDL therapy for IH over timolol alone. We present our experience using combination timolol and PDL therapy for IH, postulate a synergistic effect, and analyze the impact of age on outcomes.

show abstract

Topical Timolol for Periocular Hemangioma: Report of Further Study

Cited by 80 publications

References 6 publications

Diagnosis and Management of Infantile Hemangioma

Diagnosis and Management of Infantile Hemangioma

Topical Treatment of Infantile Hemangiomas – Where Are We Now? / Topikalni tretman infantilnih hemangioma – gde smo danas?

Novel Combination Topical Timolol and Pulsed Dye Laser Therapy for Early Effective Safe Treatment of Infantile Hemangiomas

Contact Info

Product

Resources

About